CO2021011906A2 - Anticuerpos claudina 6 y usos de los mismos - Google Patents
Anticuerpos claudina 6 y usos de los mismosInfo
- Publication number
- CO2021011906A2 CO2021011906A2 CONC2021/0011906A CO2021011906A CO2021011906A2 CO 2021011906 A2 CO2021011906 A2 CO 2021011906A2 CO 2021011906 A CO2021011906 A CO 2021011906A CO 2021011906 A2 CO2021011906 A2 CO 2021011906A2
- Authority
- CO
- Colombia
- Prior art keywords
- claudin
- antibodies
- compositions
- Prior art date
Links
- 102000003859 Claudin-6 Human genes 0.000 title abstract 2
- 108090000229 Claudin-6 Proteins 0.000 title abstract 2
- 239000000203 mixture Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
- A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/463—Cellular immunotherapy characterised by recombinant expression
- A61K39/4631—Chimeric Antigen Receptors [CAR]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
- A61K39/464402—Receptors, cell surface antigens or cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/515—Animal cells
- A61K2039/5156—Animal cells expressing foreign proteins
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/515—Complete light chain, i.e. VL + CL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Cell Biology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Oncology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
Se proporcionan anticuerpos y composiciones contra claudina 6 y usos de los mismos.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201962806048P | 2019-02-15 | 2019-02-15 | |
PCT/US2020/018087 WO2020168059A1 (en) | 2019-02-15 | 2020-02-13 | Claudin 6 antibodies and uses thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
CO2021011906A2 true CO2021011906A2 (es) | 2021-09-30 |
Family
ID=72043303
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CONC2021/0011906A CO2021011906A2 (es) | 2019-02-15 | 2021-09-10 | Anticuerpos claudina 6 y usos de los mismos |
Country Status (19)
Country | Link |
---|---|
US (2) | US11248046B2 (es) |
EP (1) | EP3924389A4 (es) |
JP (1) | JP2022521723A (es) |
KR (1) | KR20210128443A (es) |
CN (1) | CN113767113A (es) |
AU (1) | AU2020223293A1 (es) |
BR (1) | BR112021016056A2 (es) |
CA (1) | CA3129834A1 (es) |
CL (1) | CL2021002141A1 (es) |
CO (1) | CO2021011906A2 (es) |
CR (1) | CR20210471A (es) |
EA (1) | EA202192146A1 (es) |
EC (1) | ECSP21068097A (es) |
IL (1) | IL285626A (es) |
MA (1) | MA54955A (es) |
MX (1) | MX2021009831A (es) |
SG (1) | SG11202108281UA (es) |
WO (1) | WO2020168059A1 (es) |
ZA (1) | ZA202106602B (es) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2020168024A1 (en) | 2019-02-15 | 2020-08-20 | Integral Molecular, Inc. | Antibodies comprising a common light chain and uses thereof |
CA3129834A1 (en) | 2019-02-15 | 2020-08-20 | Integral Molecular, Inc. | Claudin 6 antibodies and uses thereof |
WO2022187275A1 (en) * | 2021-03-02 | 2022-09-09 | Novarock Biotherapeutics, Ltd. | Antibodies against claudin-6 and uses thereof |
JPWO2023053282A1 (es) * | 2021-09-29 | 2023-04-06 | ||
WO2023230624A2 (en) * | 2022-05-27 | 2023-11-30 | Taipei Medical University | Epha2-targeting antibodies and their applications in cancer treatment |
US12049502B2 (en) | 2022-11-30 | 2024-07-30 | Integral Molecular, Inc. | Antibodies directed to claudin 6, including bispecific formats thereof |
Family Cites Families (77)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4376110A (en) | 1980-08-04 | 1983-03-08 | Hybritech, Incorporated | Immunometric assays using monoclonal antibodies |
US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
JPS6147500A (ja) | 1984-08-15 | 1986-03-07 | Res Dev Corp Of Japan | キメラモノクロ−ナル抗体及びその製造法 |
EP0173494A3 (en) | 1984-08-27 | 1987-11-25 | The Board Of Trustees Of The Leland Stanford Junior University | Chimeric receptors by dna splicing and expression |
GB8422238D0 (en) | 1984-09-03 | 1984-10-10 | Neuberger M S | Chimeric proteins |
US4699880A (en) | 1984-09-25 | 1987-10-13 | Immunomedics, Inc. | Method of producing monoclonal anti-idiotype antibody |
JPS61134325A (ja) | 1984-12-04 | 1986-06-21 | Teijin Ltd | ハイブリツド抗体遺伝子の発現方法 |
WO1987002671A1 (en) | 1985-11-01 | 1987-05-07 | International Genetic Engineering, Inc. | Modular assembly of antibody genes, antibodies prepared thereby and use |
WO1988001649A1 (en) | 1986-09-02 | 1988-03-10 | Genex Corporation | Single polypeptide chain binding molecules |
US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
US5260203A (en) | 1986-09-02 | 1993-11-09 | Enzon, Inc. | Single polypeptide chain binding molecules |
DE3920358A1 (de) | 1989-06-22 | 1991-01-17 | Behringwerke Ag | Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung |
US5475096A (en) | 1990-06-11 | 1995-12-12 | University Research Corporation | Nucleic acid ligands |
EP1136556B1 (en) | 1991-11-25 | 2005-06-08 | Enzon, Inc. | Method of producing multivalent antigen-binding proteins |
EP1621554B2 (en) | 1992-08-21 | 2012-08-29 | Vrije Universiteit Brussel | Immunoglobulins devoid of light chains |
US6005079A (en) | 1992-08-21 | 1999-12-21 | Vrije Universiteit Brussels | Immunoglobulins devoid of light chains |
US6838254B1 (en) | 1993-04-29 | 2005-01-04 | Conopco, Inc. | Production of antibodies or (functionalized) fragments thereof derived from heavy chain immunoglobulins of camelidae |
SE9400088D0 (sv) | 1994-01-14 | 1994-01-14 | Kabi Pharmacia Ab | Bacterial receptor structures |
EP1405911A1 (en) | 1994-07-20 | 2004-04-07 | The General Hospital Corporation | Interaction trap systems for detecting protein interactions |
US7763258B2 (en) | 1997-05-20 | 2010-07-27 | The Trustees Of The University Of Pennsylvania | Virus-like particles (VLPs) comprising heterologous multiple membrane spanning proteins |
DE19742706B4 (de) | 1997-09-26 | 2013-07-25 | Pieris Proteolab Ag | Lipocalinmuteine |
AUPP221098A0 (en) | 1998-03-06 | 1998-04-02 | Diatech Pty Ltd | V-like domain binding molecules |
US6955807B1 (en) | 1998-05-15 | 2005-10-18 | Bayer Pharmaceuticals Corporation | IL-2 selective agonists and antagonists |
US6818418B1 (en) | 1998-12-10 | 2004-11-16 | Compound Therapeutics, Inc. | Protein scaffolds for antibody mimics and other binding proteins |
NZ515329A (en) | 1999-05-05 | 2004-05-28 | Tvw Telethon Inst Child Health | Isolating biological modulators from biodiverse gene fragment libraries |
EP1181358B1 (en) | 1999-05-26 | 2010-11-17 | Next Biomed Technologies NBT Oy | Methods and materials for generating sh3 domains with tailored binding properties |
SE0001877D0 (sv) | 2000-05-22 | 2000-05-22 | Klaus Mosbach | Molecular imprinting |
EP2149604A1 (en) | 2000-09-08 | 2010-02-03 | Universität Zürich | Collections of repeat proteins comprising repeat modules |
DE10053224A1 (de) | 2000-10-26 | 2002-05-08 | Univ Goettingen Georg August | Verfahren zur Exposition von Peptiden und Polypeptiden auf der Zelloberfläche von Bakterien |
US20040132094A1 (en) | 2000-12-13 | 2004-07-08 | Michael Etzerodt | Combinatorial libraries of proteins having the scaffold structure of c-type lectinlike domains |
AUPR546801A0 (en) * | 2001-06-05 | 2001-06-28 | Commonwealth Scientific And Industrial Research Organisation | Recombinant antibodies |
ATE490969T1 (de) | 2001-08-30 | 2010-12-15 | Biorexis Pharmaceutical Corp | Modifizierte transferrin-fusionsproteine |
NZ590187A (en) | 2002-10-02 | 2012-07-27 | Catalyst Biosciences Inc | Methods of generating and screening for proteases with altered specificity |
US20040209243A1 (en) | 2003-01-07 | 2004-10-21 | Andrew Nixon | Kunitz domain library |
US8574590B2 (en) | 2003-07-30 | 2013-11-05 | Integral Molecular, Inc. | Lipoparticles comprising proteins, methods of making, and using the same |
AU2005227263A1 (en) | 2004-03-05 | 2005-10-06 | Novartis Vaccines And Diagnostics, Inc. | In vitro test system for predicting patient tolerability of therapeutic agents |
US20060008844A1 (en) | 2004-06-17 | 2006-01-12 | Avidia Research Institute | c-Met kinase binding proteins |
DE102004049479A1 (de) | 2004-10-11 | 2006-04-13 | Scil Proteins Gmbh | Proteinkonjugate zur Verwendung in Therapie, Diagnose und Chromatographie |
US8367805B2 (en) | 2004-11-12 | 2013-02-05 | Xencor, Inc. | Fc variants with altered binding to FcRn |
US8377691B2 (en) | 2006-01-26 | 2013-02-19 | Integral Molecular, Inc. | Lipoparticles comprising ion channels, methods of making and using the same |
EP1892248A1 (en) | 2006-08-21 | 2008-02-27 | Eidgenössische Technische Hochschule Zürich | Specific and high affinity binding proteins comprising modified SH3 domains of FYN kinase |
GB0624500D0 (en) * | 2006-12-07 | 2007-01-17 | Istituto Superiore Di Sanito | A novel passive vaccine for candida infections |
US8680237B2 (en) | 2007-06-01 | 2014-03-25 | Gliknik Inc. | Immunoglobulin constant region FC receptor binding agents |
WO2009025759A1 (en) | 2007-08-17 | 2009-02-26 | Progenics Pharmaceuticals (Nevada), Inc. | Tight junction proteins associated with infection and entry of hepatitis c virus (hcv), methods and uses thereof |
SG187457A1 (en) | 2008-01-11 | 2013-02-28 | Univ Tokyo | Anti-cldn6 antibody |
MX2011007647A (es) | 2009-01-21 | 2011-09-01 | Amgen Inc | Composiciones y metodos para el tratamiento de enfermedades inflamatorias y autoinmunes. |
WO2010126590A1 (en) | 2009-04-27 | 2010-11-04 | Cold Spring Harbor Laboratory | Ptp1b inhibitors |
EP2322555A1 (en) * | 2009-11-11 | 2011-05-18 | Ganymed Pharmaceuticals AG | Antibodies specific for claudin 6 (CLDN6) |
AU2010318316B2 (en) | 2009-11-11 | 2016-01-14 | Astellas Pharma Inc. | Antibodies specific for Claudin 6 (CLDN6) |
CN102821788B (zh) | 2010-02-04 | 2016-11-16 | 东丽株式会社 | 癌的治疗和/或预防用药物组合物 |
EP2404936A1 (en) * | 2010-07-06 | 2012-01-11 | Ganymed Pharmaceuticals AG | Cancer therapy using CLDN6 target-directed antibodies in vivo |
US9428567B2 (en) | 2010-12-22 | 2016-08-30 | The Board Of Trustees Of The Leland Stanford Junior University | Antagonists of interleukin-2 receptor |
AU2012258087B2 (en) | 2011-05-13 | 2017-07-20 | Astellas Pharma Inc. | Antibodies for treatment of cancer expressing claudin 6 |
US9441782B2 (en) | 2011-10-14 | 2016-09-13 | Ergotron, Inc. | Tablet mounting arm systems and methods |
CA2862290A1 (en) | 2012-01-18 | 2013-10-17 | Neumedicines, Inc. | Il-12 for radiation protection and radiation-induced toxicity mitigation |
WO2014016737A1 (en) * | 2012-07-24 | 2014-01-30 | Pfizer Inc. | Novel chicken monoclonal antibodies against human phosphorylated tau and uses thereof |
US9580486B2 (en) | 2013-03-14 | 2017-02-28 | Amgen Inc. | Interleukin-2 muteins for the expansion of T-regulatory cells |
WO2015014376A1 (en) | 2013-07-31 | 2015-02-05 | Biontech Ag | Diagnosis and therapy of cancer involving cancer stem cells |
CN103483449A (zh) | 2013-08-20 | 2014-01-01 | 东北农业大学 | 两种scFv抗体、其编码基因及其在制备治疗或预防鸡传染性法氏囊病制剂中的应用 |
PE20160870A1 (es) | 2013-11-06 | 2016-09-09 | Abbvie Stemcentrx Llc | Anticuerpos anti-claudina novedosos y metodos de uso |
CN106795213B (zh) | 2014-07-21 | 2021-12-07 | 德里尼亚公司 | 选择性地活化调节性t细胞用于治疗自身免疫病的分子 |
EP3180020B1 (en) | 2014-08-11 | 2018-12-26 | Delinia, Inc. | Modified il-2 variants that selectively activate regulatory t cells for the treatment of autoimmune diseases |
CA2874083C (en) * | 2014-12-05 | 2024-01-02 | Universite Laval | Tdp-43-binding polypeptides useful for the treatment of neurodegenerative diseases |
ES2952132T3 (es) | 2015-03-06 | 2023-10-27 | Public Univ Corp Yokohama City Univ | Nuevo anticuerpo anti-pad4 |
GB201607534D0 (en) | 2016-04-29 | 2016-06-15 | Immunocore Ltd & Adaptimmune Ltd | Peptides |
MA43385A (fr) * | 2015-12-04 | 2018-10-10 | Abbvie Stemcentrx Llc | Nouveaux anticorps anti-claudine et méthodes d'utilisation |
EP3452084A4 (en) * | 2016-05-02 | 2020-01-01 | Tetragenetics, Inc. | ANTI-KV 1.3 ANTIBODIES AND METHODS OF PRODUCING AND USING THE SAME |
JP7422480B2 (ja) | 2016-05-04 | 2024-01-26 | アムジエン・インコーポレーテツド | 制御性t細胞の増殖のためのインターロイキン-2変異タンパク質 |
WO2018054484A1 (en) | 2016-09-23 | 2018-03-29 | Biontech Ag | Bispecific trivalent antibodies binding to claudin 6 or claudin18.2 and cd3 for treatment of claudin expressing cancer diseases |
WO2018067198A1 (en) * | 2016-10-03 | 2018-04-12 | The Regents Of The University Of California | Inhibitory antibodies and methods of use thereof |
WO2019048040A1 (en) | 2017-09-06 | 2019-03-14 | Ganymed Pharmaceuticals Gmbh | ANTIBODIES USEFUL IN THE DIAGNOSIS OF CANCER |
IL313238A (en) | 2017-09-18 | 2024-07-01 | Univ California | Claudin 6 antibodies and methods of cancer treatment |
WO2020075325A1 (ja) | 2018-10-09 | 2020-04-16 | 公立大学法人福島県立医科大学 | 子宮体癌患者の予後予測バイオマーカー |
WO2020168024A1 (en) | 2019-02-15 | 2020-08-20 | Integral Molecular, Inc. | Antibodies comprising a common light chain and uses thereof |
CA3129834A1 (en) | 2019-02-15 | 2020-08-20 | Integral Molecular, Inc. | Claudin 6 antibodies and uses thereof |
CA3134055A1 (en) | 2019-03-20 | 2020-09-24 | The Regents Of The University Of California | Claudin-6 antibodies and drug conjugates |
BR112021023173A2 (pt) | 2019-07-10 | 2022-01-04 | Chugai Pharmaceutical Co Ltd | Moléculas de ligação à claudin-6 e usos das mesmas |
-
2020
- 2020-02-13 CA CA3129834A patent/CA3129834A1/en active Pending
- 2020-02-13 CN CN202080025731.5A patent/CN113767113A/zh active Pending
- 2020-02-13 AU AU2020223293A patent/AU2020223293A1/en active Pending
- 2020-02-13 EP EP20755889.1A patent/EP3924389A4/en active Pending
- 2020-02-13 EA EA202192146A patent/EA202192146A1/ru unknown
- 2020-02-13 MX MX2021009831A patent/MX2021009831A/es unknown
- 2020-02-13 CR CR20210471A patent/CR20210471A/es unknown
- 2020-02-13 SG SG11202108281UA patent/SG11202108281UA/en unknown
- 2020-02-13 WO PCT/US2020/018087 patent/WO2020168059A1/en active Application Filing
- 2020-02-13 KR KR1020217029523A patent/KR20210128443A/ko unknown
- 2020-02-13 US US16/790,066 patent/US11248046B2/en active Active
- 2020-02-13 BR BR112021016056A patent/BR112021016056A2/pt unknown
- 2020-02-13 MA MA054955A patent/MA54955A/fr unknown
- 2020-02-13 JP JP2021547877A patent/JP2022521723A/ja active Pending
-
2021
- 2021-08-12 CL CL2021002141A patent/CL2021002141A1/es unknown
- 2021-08-15 IL IL285626A patent/IL285626A/en unknown
- 2021-09-08 ZA ZA2021/06602A patent/ZA202106602B/en unknown
- 2021-09-10 CO CONC2021/0011906A patent/CO2021011906A2/es unknown
- 2021-09-14 EC ECSENADI202168097A patent/ECSP21068097A/es unknown
-
2022
- 2022-01-04 US US17/568,438 patent/US20220127355A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
ZA202106602B (en) | 2023-12-20 |
US20220127355A1 (en) | 2022-04-28 |
AU2020223293A1 (en) | 2021-08-19 |
US20200262915A1 (en) | 2020-08-20 |
US11248046B2 (en) | 2022-02-15 |
EP3924389A4 (en) | 2023-06-14 |
MX2021009831A (es) | 2021-09-10 |
ECSP21068097A (es) | 2021-11-18 |
KR20210128443A (ko) | 2021-10-26 |
BR112021016056A2 (pt) | 2021-12-14 |
IL285626A (en) | 2021-09-30 |
WO2020168059A1 (en) | 2020-08-20 |
CA3129834A1 (en) | 2020-08-20 |
EA202192146A1 (ru) | 2021-11-09 |
CL2021002141A1 (es) | 2022-04-01 |
SG11202108281UA (en) | 2021-08-30 |
CN113767113A (zh) | 2021-12-07 |
MA54955A (fr) | 2021-12-22 |
CR20210471A (es) | 2021-12-08 |
EP3924389A1 (en) | 2021-12-22 |
JP2022521723A (ja) | 2022-04-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CO2021011906A2 (es) | Anticuerpos claudina 6 y usos de los mismos | |
CL2020000596S1 (es) | Auriculares. | |
CL2021003191A1 (es) | Inhibidores de tead y usos de los mismos | |
CL2021003190A1 (es) | Inhibidores de tead y usos de los mismos | |
MA54952A (fr) | Conjugués d'il-2 et méthodes d'utilisation de ceux-ci | |
CL2020000595S1 (es) | Estuche de auriculares. | |
CL2022000448A1 (es) | Autoinyector (divisional solicitud no. 201903061) | |
BR112019012343A2 (pt) | anticorpos il-11ra | |
BR112019012342A2 (pt) | anticorpos il-11 | |
WO2017124002A8 (en) | Multispecific immunomodulatory antigen-binding constructs | |
DK3781561T3 (da) | Modulatorer af methylmodificerende enzymer, sammensætninger og anvendelser deraf | |
CO2020012347A2 (es) | Anticuerpos anti-hla-g y usos de los mismos. | |
PH12020551716A1 (en) | Anti-ror antibody constructs | |
MX2021012659A (es) | Composiciones de seda para el cuidado del cabello. | |
EA201892500A1 (ru) | Применение фракции лигнина в качестве антифитопатогенного агента и содержащие ее антифитопатогенные композиции | |
BR112022012410A2 (pt) | Degradadores smarca e usos dos mesmos | |
MX2021016050A (es) | Formulaciones transdermicas. | |
CL2019001915A1 (es) | Fraccionamiento de material basado en biomasa | |
EA202092508A1 (ru) | Составы на основе антител к pd-l1 человека | |
BR112021011124A2 (pt) | Anelossomos e métodos de uso | |
UY38759A (es) | Tienilhidroxiisoxazolinas y derivados de las mismas | |
MA52951A (fr) | Anticorps anti-cd37 et anticorps anti-cd20, compositions et méthodes d'utilisation de ceux-ci | |
CL2019001469S1 (es) | Cepillo de dientes. | |
EA202190217A1 (ru) | Формы ивосидениба и фармацевтические композиции | |
CL2021002501A1 (es) | Compuestos novedosos y métodos de uso de los mismos. |